• Proceeds from the offerings will support the company’s operations into the first quarter of 2025.
• Clene also amended its existing debt facility with Avenue Venture Opportunities Fund, L.P. to reduce or defer future monthly principal payments and to extend principal amortization period and the final maturity date into the first half of 2025.
• The company’s lead drug candidate, CNM-Au8^® has been shown to restore and protect neurological function, offering new hope for patients with ALS and other neurodegenerative conditions.
• Clene is seeking an accelerated approval pathway for CNM-Au8 for ALS, with a meeting scheduled with the FDA before the end of November.

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) multiple sclerosis (“MS”) and Parkinson’s Disease (“PD”), announced the successful closing of a $7.3 million registered direct offering and concurrent private placements, designed to boost its capital position during a crucial phase in its on-going operations.

The registered direct offering and concurrent private placements of common stock and warrants with a healthcare-focused institutional investor and existing shareholders, including insiders, brought total gross proceeds of $7.3 million, with the potential for additional capital in the future through the exercise of warrants (https://ibn.fm/m8dCM).

The offering was led by a healthcare-focused institutional investor with participation from SymBiosis; founding investor Kensington Capital Holdings; Clene’s Chairman of the Board of Directors, Chief Executive Officer and Chief Scientific Officer and Founder; along with support from several other previously existing shareholders.

Clene also announced an amendment of its existing debt facility with Avenue Venture Opportunities Fund, L.P. such that future monthly principal payments are reduced or deferred, and the principal amortization period and maturity date of the loan will be extended into the first half of 2025.

This financing and debt restructuring is expected to provide Clene with essential funding for its operations into the first quarter of 2025 which will support upcoming regulatory milestones, including the upcoming meeting with the U.S. Food and Drug Administration (“FDA”) to discuss the potential to file a new drug application for lead candidate CNM-Au8 for ALS under an accelerated approval pathway.

This financing follows two encouraging Phase 2 clinical trials, RESCUE-ALS and HEALEY ALS Platform Trials, where participants who were administered CNM-Au8, saw significant improvement in survival rates, functional status and combined assessment of function and survival.

Developed as an oral suspension of gold nanocrystals, CNM-Au8 works by improving cellular energy production and utilization, which is critical for maintaining neuronal health. In both clinical trials and compassionate use programs, CNM-Au8 has already been shown to improve central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the nicotinamide adenine dinucleotide (“NAD”) pathway while reducing oxidative stress. By targeting mitochondrial dysfunction, CNM-Au8 aims to provide neuroprotection and promote remyelination, potentially altering the course of neurodegenerative conditions.

Commenting on the closing of the financing and upcoming plans, Chairman of the Board David Matlin said the company appreciated the support it obtained from its new healthcare-focused institutional investor as well as existing shareholders. “The capital raised in this offering along with the debt principal deferral from Avenue will allow the company to fund itself while in discussions with the FDA to potentially file an NDA under the accelerated approval pathway by year end,” Matlin added. “Most importantly, this financing also enables people with ALS who currently take CMN-Au8 under our compassionate use programs to continue receiving drug while Clene discusses its data with the FDA.”

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

• AI Transforms Mining: AI speeds up mineral discovery by analyzing large datasets, predicting drill targets, and improving operational efficiency.
• A McKinsey report estimates that AI could unlock $290 billion to $390 billion in annual savings for producers of key resources by 2035.
• Emperor Metals’ Advantage: At Duquesne West, Emperor Metals used AI and DomainMCF to develop a 3D geological model, accelerating discovery and unlocking new high-priority exploration targets.

As the global mining industry faces mounting pressures to boost productivity, reduce costs and minimize its environmental impact, artificial intelligence (“AI”) is emerging as a necessary evolution. A 2022 McKinsey report estimates that AI could unlock $290 billion to $390 billion in annual savings for producers of key resources by 2035.

At the forefront of AI-driven exploration is Emperor Metals Inc. (CSE: AUOZ) (OTCQB: EMAUF) (FSE: 9NH), a junior mining firm based in Quebec. The company has integrated AI into its flagship Duquesne West Gold Project in Quebec’s Abitibi Greenstone Belt, a prolific Canadian gold mining distinct currently hosting 15 producing gold mines.

Mining’s Long-Standing Challenges Meet AI’s Potential

The mining industry has long grappled with inefficiencies in resource identification, costly drilling processes and complex geological challenges. While advancements such as LiDAR mapping, drone surveys, and the recently piloted automated drilling have improved certain aspects of mining operations, exploration has remained largely manual and data-heavy.

Traditionally, geologists would spend months painstakingly poring over tens of thousands of meters of drill core and data points, searching for signs of valuable mineral deposits—a process that was slow, labor-intensive and prone to error. In an era where global demand for materials like gold, copper and lithium is rising, these inefficiencies have become major bottlenecks.

Enter AI.

AI is poised to reshape the industry, not only by improving day-to-day operations like predictive maintenance and safety management but also by fundamentally transforming how companies approach exploration and the discovery of new deposits. AI’s ability to process and analyze vast datasets allows it to identify mineralization patterns, predict drill targets and optimize extraction strategies with unprecedented accuracy.

Emperor Metals: A Pioneer in AI-Driven Exploration

For Emperor Metals, AI is not just a tool but the core of their strategy at the Duquesne West Gold Project. They have leveraged Maptek’s DomainMCF machine learning technology and developed the first-ever 3D geological model of the deposit. This software enabled Emperor to analyze large volumes of geological data with unprecedented speed and accuracy.

A major breakthrough from this AI-driven analysis was identifying the potential to shift from a costly underground mining model to a more efficient open-pit approach. This shift could significantly reduce operational costs while providing access to high-grade gold zones that might have otherwise been missed.

“We’re not just drilling blindly anymore,” says John Florek, CEO of Emperor Metals. “AI has given us a roadmap at a rapid pace. Traditional methods would have taken much longer and may not have yielded the same high-grade results. Thanks to AI, we intercepted grades of 15.8 grams per tonne over 10.85 meters—data that reshaped our exploration strategy and confirmed the potential for an open-pit operation.”

The use of DomainMCF allowed the team to quickly develop the first-ever mineralized model within a month, and the full 3D geological model within four months, a process which used to take years. This technology also reanalyzed historical drilling data, uncovering overlooked value and identifying new high-priority targets. These insights not only accelerated Emperor Metals’ discovery process but also fundamentally changed the company’s trajectory by opening up new exploration opportunities.

In 2023, Emperor Metals completed an 8,600-meter drill program, building on historical data from over 100,000 meters of previous drilling. In 2024, they drilled an additional 8,000 meters, further advancing the project’s potential which will further feed the machine learning models.

Looking Ahead: A Bold Vision for the Future

As AI evolves, its importance in mining will only increase. For Emperor Metals, AI is the future of responsible, data-driven exploration. “We’re just getting started,” says CEO John Florek. “It’s about finding gold smarter and more sustainably.” With AI as a cornerstone, Emperor is well-positioned to seize new opportunities, setting a modern standard for mining operations.

For more information, visit www.EmperorMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to EMAUF are available in the company’s newsroom at https://ibn.fm/EMAUF

• Alcohol detection and monitoring devices have been in use for years, but the need for faster, discreet technology capable of delivering real-time results became more apparent in the mid-2010s
• In 2015 and 2016, the NIAAA announced challenges seeking alcohol monitoring solutions that provide real-time results; the winning entries were wearable wristbands still at the prototype stage
• Fast-forward to today, and SOBRsafe, a company providing next-generation alcohol detection technology, commercializes its market-validated SOBRcheck(TM) stationary alcohol screening device and the SOBRsure(TM) wearable wristband
• SOBRsafe’s devices feature highly precise sensors that are calibrated for early, low alcohol detection, beginning at about 20 minutes, compared to 45-60 minutes for the leading mandatory ankle monitor
• The company believes its disruptive breakthrough technology could become the global standard for alcohol monitoring and detection, replacing legacy products and testing methods

In 2015 and 2016, the National Institute on Alcohol Abuse and Alcoholism (“NIAAA”), a part of the National Institutes of Health (“NIH”), challenged innovators and entrepreneurs to create a “wearable or otherwise discreet device capable of measuring blood alcohol level in real-time.” The challenge aimed to help solve the disadvantages of the then-preferred technologies for alcohol monitoring.

“Current technology for continuous alcohol monitoring takes a reading every 30 minutes. We are seeking a solution that improves on this interval and most closely approximates real-time monitoring and data collection,” stated the circular from NIAAA explaining the rationale behind the 2015 challenge (https://ibn.fm/EhUO8).

The winners designed wearable wrist monitors that measure transdermal alcohol concentrations (“TAC”) (https://ibn.fm/fpXye). While these winning entries were prototypes, the competition perhaps inspired the modern alcohol detection and monitoring landscape. Today, there are validated, commercially available transdermal alcohol monitoring devices available on the market, some more capable than others.

One company in particular, SOBRsafe (NASDAQ: SOBR), commercializes its SOBRcheck(TM) stationary screening and SOBRsure(TM) wearable monitoring solutions, which utilize a proprietary transdermal technology that simplifies the alcohol detection process. According to the company, the SOBRsafe transdermal detection technology pairs a NIAAA-awarded transdermal gas sensor with proprietary algorithms to capture alcohol vapor excreted through skin pores alongside other contents of sweat.

The highly precise sensor is engineered and calibrated for early, low alcohol detection, beginning at about 20 minutes, compared to 45-60 minutes for the leading mandatory ankle monitor. The company’s technology, therefore, detects alcohol 2-3x faster than other transdermal alcohol detection solutions (https://ibn.fm/Vd9GI).

The SOBRcheck(TM) stationary screening device is designed for facility access control, centralized fleets, and monitoring patients in point-of-care behavioral health facilities. It features the aforementioned gas sensor, which determines the presence or absence of alcohol, and a biometric sensor that scans a fingerprint to authenticate a user’s identity. The device provides administrators with real-time, time-stamped results, delivered via the company’s SOBRsafe software. One adopter of the SOBRcheck(TM) solution, Alternatives Inc., in fact, noted that SOBRcheck(TM) is faster and more sanitary than breathalyzers (https://ibn.fm/tM191).

The SOBRsure(TM) remote monitoring device, on the other hand, has the same footprint as a wearable wristband. It is designed to discreetly and continuously monitor the presence of alcohol in the system, freeing users from scheduled testing and building trust faster thanks to its continuous monitoring attribute. It also eliminates the embarrassment that accompanies using blow devices or providing urine samples.

Like the SOBRcheck(TM) device, the SOBRsure(TM) features the award-winning gas sensor, as well as GPS tracking capabilities. It relays the results continuously to an app-based reporting interface and sends notifications to parents or administrators whenever it detects alcohol. It also sends alerts containing location data whenever it is removed.

Since the fourth quarter of 2023, SOBRsafe has been marketing its alcohol detection and monitoring solutions to the behavioral health market. “In 2024, and consistent with our strategy, we have now established our technology, with our first revenue-generating customers in behavioral health growing to 35 accounts in the first and second quarters of this year. In addition, we entered the equivalent verticals in Australia and New Zealand and are gaining traction through a channel partner that we’re very, very excited about,” said SOBRsafe CEO Dave Gandini in a recent video update (https://ibn.fm/My3XB).

The company is also targeting further international expansion and has invested in a marketing campaign that aims to present its solutions to more than 45,000 behavioral health decision-makers in the U.S. “We believe that our approach will increase demand, drive sales and gain market share for us in the fourth quarter and on into 2025,” Gandini continued.

The company believes its disruptive breakthrough technology could become the global standard for alcohol monitoring and detection, replacing legacy products and testing methods. And with its international expansion and robust marketing campaign underway, coupled with the strong adoption in the core behavioral health vertical since late 2023, the company is a worthy consideration for investors.

For more information, visit the company’s website at www.SOBRsafe.com.

NOTE TO INVESTORS: The latest news and updates relating to SOBR are available in the company’s newsroom at https://ibn.fm/SOBR

The 21st BioPharma Drug Discovery Nexus will be held on October 22-23, 2024, at the Holiday Inn Piscataway – Somerset, in New Jersey. New Jersey was selected as the venue for the event, as this northeastern state has been at the helm of biotech and pharma innovations and research. Experts from the region and all across the globe will grace the event and discuss challenges and opportunities in the field of drug discovery.

The event is organized by BioPharma Nexus, a trusted player in fostering connections between pharmaceutical and biotech companies, along with key service providers. Their goal is to provide the best healthcare to patients all over the globe. Service providers and businesses in biotech, pharma and healthcare, can identify and connect with partners to foster scientific and healthcare collaborations.

The event agenda:

• Automation & Computational Drug Design
• Antibody Therapeutics & Protein Engineering
• Novel Targets: Exploring Modalities in Drug Discovery
• Advancement in Cell & Gene Therapy

The 21st BioPharma Dug Discovery Nexus engages the attendees in interactive discussions, presentations and keynote speaker sessions. The speakers presiding over the keynote sessions are eminent representatives, with important insight and experience in their industry. These stalwarts from the biopharma industry will share critical information and discuss the latest trends in the industry.

New and established entities in the drug discovery spectrum can expand their connections in the pharma space. It is a phenomenal learning experience as they can get answers from top industry experts. The networking breaks offer attendees a comfortable window to connect directly with industry leaders.

To learn more, please visit https://ibn.fm/TKTOR.

• “The first deep drill hole of the year adds another success to the 2024 exploration program at Storm,” said Aston Bay CEO.
• So far this year, the drilling program has completed a total of 128 RC drill holes and 14 diamond drill holes at Storm and Tempest, exceeding the planned target.
• Data obtained from these drill holes will be “fed back into the model,” providing additional refinement to targeting for even better copper intercepts at depth.

Accelerated drilling at the Storm Copper Project has discovered Cyclone-style copper mineralization at depth and confirmed the prospectivity of the Central Graben area, reported Aston Bay Holdings (TSX.V: BAY) (OTC: ATBHF) in its latest update regarding the project’s 2024 drilling exploration program (https://ibn.fm/rxa1a). The program has focused on expansion at the Cyclone and Chinook Prospects and delineation drilling at the Lightning Ridge discovery and Thunder Prospect.

“The first deep drill hole of the year adds another success to the 2024 exploration program at Storm,” said Aston Bay CEO Thomas Ullrich. “The style of copper mineralization intercepted, and its stratigraphic location is similar to Cyclone — this may be the fault-offset southern portion of the deposit and could add to a potential future resource.

“In addition to extensions to known mineralization, this discovery highlights the discovery potential of the deeper stratigraphic levels in the Central Graben area, an expanse of over 10-square kilometers,” Ullrich continued. “Every deep drill hole has hit copper mineralization at approximately the same depth, and we continue to improve our geophysical modeling to hit thicker and higher-grade intercepts in this very large and prospective horizon.”

The drilling program is being conducted by American West Metals Limited. Aston Bay and American West are working together on the Storm Project property, having formed a 20/80 unincorporated joint venture. According to the agreement, Aston Bay maintains a free carried interest until a decision to mine upon completion of a bankable feasibility study.

So far this year, the two companies have reported a total of 128 RC drill holes and 14 diamond drill holes completed at Storm and Tempest, exceeding the planned target of 20,000 meters (https://ibn.fm/i7CTT). Drilling will continue in the coming weeks, with additional assays expected in batches.

Aston Bay noted that recent results from the Cyclone Deposit have confirmed further intersections of high-grade copper up to 13.5% Cu, both within and outside the current resource envelope, while exploration drilling targeting a moving-loop electromagnetic (“MLEM”) anomaly in the Southern Graben area has intersected strong visual copper sulfides at the end of the hole. Aston Bay has named the new discovery and area Squall and is reporting that the drill hole is being extended to confirm the full extent of the mineralization.

“The value of these deeper discoveries is not limited to the potential value of the copper alone,” Ullrich observed. “The geophysical signature of exploration success that we obtain from these drill holes will be fed back into the model to further refine our targeting for even better copper intercepts at depth.”

These are among the benefits that Aston Bay is eyeing as it focuses on exploring for high-grade critical and precious metal deposits in both Canada and the United States. The company is aggressively advancing the high-grade Storm Copper Project in Nunavut, Canada, toward development with partner American West Metals. The company is free carried for all expenditures at the project until decision to mine. Aston Bay is looking to replicate the success of Storm with its Epworth Copper Project, also located in Nunavut, where surface samples have yielded up to 61% copper with 5600 g/t silver as well as cobalt, zinc, gold. The company is also exploring the high-grade (up to 62.51 g/t Au) Buckingham Gold Vein and critical metals prospects in central Virginia.

For more information, visit AstonBayHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to ATBHF are available in the company’s newsroom at https://ibn.fm/ATBHF

• In September 2024, Foremost announced an option agreement with Denison Mines for 10 uranium projects in Saskatchewan’s Athabasca Basin.
• The company has aggressive exploration plans across its 330,000-acre uranium portfolio, with both shallow and deep targets.
• The Athabasca Basin is known for hosting some of the richest uranium deposits in the world, with strong infrastructure supporting exploration.
• Foremost’s partnerships with Denison Mines and local geological firms, along with its strong management team, position it well for future success.
• The company also holds a secondary portfolio of lithium projects, covering over 50,000 acres, providing additional long-term growth potential.

Foremost Clean Energy (NASDAQ: FMST) (CSE: FAT), formerly Foremost Lithium Resource & Technology Ltd., is an emerging North American energy exploration company focused on supporting the clean energy transition. Foremost holds an option to acquire an interest in 10 prospective uranium properties, covering over 330,000 acres in the uranium-rich Athabasca Basin of Saskatchewan.

The company aims to address the growing demand for uranium, a critical element in global energy transition efforts. In partnership with Denison Mines (NYSE American: DNN), Foremost is pursuing a disciplined and dynamic exploration strategy. Foremost’s mission is to make significant discoveries through active exploration of its promising, underdeveloped land holdings in the Athabasca Basin. Its uranium portfolio includes projects at various stages of exploration, from grassroots initiatives to advanced, drill-ready targets.

As the world shifts toward a clean energy future, uranium will play a key role as a low-cost, emission-free fuel for electricity generation. Foremost’s development plans aim to provide low-cost uranium solutions, capitalizing on the global movement to decarbonize power grids.

In addition to its uranium assets, Foremost holds a secondary portfolio of lithium projects, spanning more than 50,000 acres across Manitoba and Quebec.

Foremost is headquartered in Vancouver, British Columbia.

Projects

Foremost’s portfolio, under its option agreement with Denison Mines, includes 10 properties, many located near high-profile uranium operations like the McClean Lake mill and Cigar Lake mine. Seven of these properties are situated in the eastern portion of the Athabasca Basin, close to well-established infrastructure, while three lie in the northwestern portion of the basin – an area with high potential for new discoveries but little previous exploration.

Through the option agreement, Foremost may earn up to 70% of Denison’s interest in the properties. Denison currently owns 100% of nine properties. The agreement includes three phases during which Foremost must issue shares to Denison, appoint Denison representatives to its board, provide cash or share payments, and incur specific exploration expenditures to increase its ownership stake.

Market Opportunity

According to RationalStat, the global uranium mining market was valued at $8.09 billion in 2023 and is projected to grow to $11.38 billion by 2030, with a CAGR of over 5%.

Uranium, used in nuclear reactors, produces energy through nuclear fission and is considered a clean energy source as it emits no greenhouse gases during operation. The push to reduce carbon emissions and combat climate change is driving the demand for nuclear energy, and thus, uranium.

The uranium market is also poised for growth due to the phasing out of fossil fuels, mine closures, production disruptions, and geopolitical factors such as trade sanctions on Russia and civil unrest in Niger, which have highlighted the urgency for reliable uranium supplies.

Canada, producing about 15% of the world’s uranium annually, is the second-largest global uranium producer, after Kazakhstan.

Management Team

Jason Barnard, CEO, President, and Executive Board Member of Foremost, has over 31 years of capital markets experience. He has been directly involved in raising over $500 million for mining and exploration companies. Mr. Bernard began his career with McDermid St. Laurence Securities and later worked at Canaccord Genuity. He has been with Foremost since 2016 and is its largest shareholder. He holds a bachelor’s degree in economics from Carleton University.

Dong Shim, CPA, CA, serves as CFO. He is a partner at Shim & Associates LLP and is registered as a CPA in British Columbia and Illinois. Mr. Shim brings extensive accounting and auditing expertise, having worked with both U.S. and Canadian junior mining and tech companies.

Christina Barnard, COO, has over 20 years of experience in business management, media and marketing. Her career includes a decade as a senior marketing and media advisor for a national public company and roles in corporate communications and strategy for several public companies.

For more information, visit the company’s website at https://foremostcleanenergy.com.

NOTE TO INVESTORS: The latest news and updates relating to FMST are available in the company’s newsroom at https://ibn.fm/FMST

The success of the NECANN 2023 convention has paved for a larger NECANN 2024 convention. The convention will be held at the spacious NYS Fairgrounds in Syracuse accommodating a mammoth number of traders, enthusiasts, growers, marketers, entrepreneurs, and investors from the cannabis and hemp spectrum.

One of the most coveted cannabis conventions, NECANN events are known for offering the best educational, interactive and business platform for cannabis enthusiasts. They broaden the horizons of every region they visit, offering phenomenal opportunities to the local business community.

This time, the NECANN event will be held in the Empire State on October 25-26, 2024, once again providing a common forum for discussion, exploration, networking, and collaborative deals on recreational and medicinal marijuana.

Exhibitors from New York State and other areas can set up booths and exhibit their products and services at the NYS Fairgrounds. They can showcase their innovative ideas to cannabis influencers, leaders and some of the biggest investors in the cannabis industry.

Attendees can create a personalized schedule for themselves, attending only those sessions that they have ‘bookmarked’. The convention will host interactive sessions, keynote speaker sessions, and discussion panels where experts navigate pivotal topics of the cannabis and hemp landscape. They will speak about the latest regulatory changes, Cannabis operator accounting, finance technology, cybersecurity, and so on.

Jack Grover, Founder & CEO of Grove Bags, will share insights into the art and science of cannabis preservation. Experts will also throw light on the justification and strategies for amending tax returns to recapture lost deductions. Presenter Brooke Anderson will take the audience on a journey describing her tryst with cannabis and its healing impact on her life and health.

To learn more, please visit https://ibn.fm/xghsD

Solution providers and innovators of the pharma and healthcare industry, as well as experts in clinical trials, are invited to attend the 21st Biopharma Clinical Trials Nexus at the Holiday Inn Piscataway, Somerset, in New Jersey. This is an invite-only event that will be held from October 22, 2024, to October 23, 2024.

BioPharma Nexus focuses on creating synergies between leading pharmaceutical and biotechnology entities, along with service providers. Their objective is to provide high-quality healthcare to patients all over the globe. At the BioPharma Nexus conferences, players can explore, discover, and generate partnerships for scientific and healthcare collaborations. 

New Jersey has been selected as the venue for hosting the event owing to several reasons. New Jersey is a powerful pharmaceutical corridor and has been pivotal in supporting biotech innovations. Experts and leaders of the biotech & pharma spectrum will attend the event to discuss useful insights on evolving healthcare and share effective strategies to overcome hurdles in clinical operations, patient-centricity, clinical outsourcing, and digital innovation. This event serves as a viable platform for clinical trial service providers to connect with industry leaders and engage in business collaborations.

The attendees at the conference will consist of senior executives and mid-level management from industries in clinical operations, digital health, patient outsourcing, and patient engagement in the US and Europe.

The event agenda consists of presentations by company executives where they showcase their innovative ideas, technology and goals. Aspiring newcomers as well as veterans will speak about their impeccable results in clinical trials. Eminent industry dignitaries will participate in panel discussions and roundtable talks where they delve into finding solutions and strategies for several industry issues. Attendees can engage with peers and brilliant industry minds during the networking breaks and lunch sessions.

To learn more, please visit https://ibn.fm/nRQpt.

• DiPasquale was featured in publications discussing his journey from the tech industry to entrepreneurship with Epic Golf Club and now GolfLync.
• Since its inception in 2018, Epic Golf Club, partnering with 200 private clubs in 43 states, plus first-rate clubs in 13 countries, has become known for its exclusive membership and five-star experiences, now having grown to 1,000 members.
• DiPasquale has brought that same sense of golfing dedication to GolfLync, an unmatched social networking platform, uniting golf enthusiasts in a top-tier golfing community of players and clubs.

GolfLync CEO and Co-Founder Noah DiPasquale, a visionary known for reimagining industries, is dedicated to providing an epic experience to all members of his exclusive Epic Golf Club, and now fostering a dynamic golfing community with GolfLync, a pioneering golf social networking platform where golf enthusiasts can come together and enjoy the game at its highest level.

In a series of recent articles highlighting DiPasquale’s journey from the tech industry to entrepreneurship and the unique experience offered by Epic Golf Club, the entrepreneur discusses what sets his projects apart in the golfing community, what inspired him to create Epic Golf Club, as well as the development and latest plans for GolfLync.

DiPasquale was born in California and moved to Chapparel, Arizona, at the age of five. Raised in modest circumstances with no golf courses or family players nearby, he discovered golf later in life. After graduating from Northern Arizona University, he dabbled in the sport with friends but didn’t pursue it seriously until years later with business clients. In 2016, DiPasquale launched his own management consulting firm, which he sold in 2018 to focus fully on his new venture, Epic Golf Club (https://ibn.fm/mTcVE).

Headquartered in Scottsdale, Epic Golf Club quickly gained a reputation for prestige and exclusivity. The club’s unique reciprocal membership model allows members to play at the finest private golf courses around the world, fostering a community of golfing elites. “The inspiration behind Epic Golf Club was to create a community where golf enthusiasts could come together and enjoy the game at its highest level,” DiPasquale said (https://ibn.fm/piSh1). Epic Golf Club partners with 200 private clubs in 43 states plus first-rate clubs in 13 countries including the Netherlands, Germany, China, Morocco, Canada, and Mexico.

DiPasquale further explained that what sets Epic Golf Club apart is an unwavering commitment to delivering a white-glove, five-star experience to members. “We wanted to offer more than just private course experiences,” he said. “We aimed to provide a full-fledged, luxury experience that includes exclusive member-only events, white-glove concierge services, and a sense of strong camaraderie among our members.”

Although exclusive, the demand to join Epic Golf Club has grown. Beginning with just 20 people in 2019, the club now has 1,000, and receives about 1,500 applications every month, out of which only 20 are selected. And as the membership grows, the number of those accepted will decrease, DiPasquale explained.

Beyond business, DiPasquale also discussed his philanthropic work through the Epic Foundation, which supports Folds of Honor, HopeKids and Youth on Course, aiming to support families of disabled or fallen service members, give hope to children with severe medical conditions, and provide inclusive golf training for the next generation of golfers (https://ibn.fm/BqlbZ). Epic also offers a student athlete scholarship for two high school seniors entering college every year. “The Epic Foundation lies at the core of Epic Golf Club’s values and is incredibly important to me personally,” DiPasquale said. “Even before Epic took off, prioritizing community support was paramount. To qualify as a member of the club, sharing these values is essential.”

DiPasquale has brought the same love for golf, and the desire to build a strong community for golfers, to GolfLync. Working much like a dating app for true golf lovers, GolfLync matches games and players, helping golfers grow their networks and find other players with similar interests and on-course preferences. Not surprisingly, the app has proven successful, with 140,000 downloads in its first 12 months. Following the same model, DiPasquale, together with Michael Quiel, a finance veteran known for his resilience and commitment to justice, have now launched SportLync, aiming to connect athletes worldwide across various sports, including tennis and hiking, with advanced AI-driven tools.

You can download the GolfLync app using the following text-anchored links:

• Android: GolfLync – Apps on Google Play 
• iPhone: GolfLync 

For more information about GolfLync, visit GolfLync, download the app, and connect with community on Facebook, X and LinkedIn. 

NOTE TO INVESTORS: The latest news and updates relating to GolfLync are available in the company’s newsroom at https://ibn.fm/GOLF

• This year enrollment in Medicare Advantage plans reached 32.8 million members, representing 52% of all Medicare recipients.
• Medicare Advantage plans typically integrate various health services under one umbrella.
• Astiva Health’s approach helps members manage existing health conditions and also focuses on promoting overall wellness.

Over the past two decades, Medicare Advantage has transformed from a niche option into a primary choice for millions of seniors across the United States. Medicare Advantage plans bundle Part A, Part B and sometimes Part D coverage into one plan, along with often offering extra benefits that original Medicare doesn’t cover. A fast-growing Medical Advantage prescription drug (“MAPD”) plan, Astiva Health offers a type of Medicare Advantage plan with prescription drug coverage, so members have no need for a separate Part D plan.

As of 2024, enrollment in Medicare Advantage plans has reached an unprecedented 32.8 million beneficiaries, representing 52% of all Medicare recipients, reported a recent Kaiser Family Foundation report (https://ibn.fm/91O0t). This statistic illustrates a significant increase in popularity, as enrollment in Medicare Advantage has more than doubled since 2004. Factors driving this rise include an aging population, rising healthcare costs, and the growing appeal of the added benefits these plans provide.

One of the primary advantages of Medicare Advantage plans is their ability to offer a more holistic approach to healthcare. Unlike original Medicare, which can sometimes lead to fragmented care, Medicare Advantage plans typically integrate various health services under one umbrella. This can include additional coverage for dental, vision and hearing services, as well as wellness programs and preventive care initiatives. The integration of these services makes it easier for members to manage their healthcare and access the necessary resources.

Another key element contributing to the growth of Medicare Advantage is the emphasis on cost effectiveness. Many members find that these plans provide lower out-of-pocket expenses compared to traditional Medicare. With a fixed monthly premium and capped out-of-pocket costs, members have a clearer understanding of their healthcare expenses. The allure of predictable costs and additional services makes Medicare Advantage an appealing option for seniors navigating the complexities of healthcare.

In this evolving market, companies such as Astiva Health are stepping up to meet the growing demand for quality Medicare Advantage plans. Astiva Health offers a range of options that prioritize member satisfaction and comprehensive care. Their plans are designed to cater to the unique needs of seniors, providing access to extensive networks of healthcare providers and specialized services.

Astiva Health stands out by emphasizing preventive care and chronic disease management. The company’s approach not only helps its members manage existing health conditions but also focuses on promoting overall wellness. By offering personalized support and resources, Astiva Health ensures that members are equipped to make informed decisions about their healthcare.

The increasing enrollment in Medicare Advantage is indicative of a broader trend toward value-based care, where the focus is on improving health outcomes rather than merely providing services. As members become more informed and engaged in their healthcare choices, the demand for plans that offer comprehensive and coordinated care will likely continue to rise.

Organizations such as Astiva Health play a crucial role in this upward trend by providing high-quality Medicare Advantage plans that cater to the diverse needs of older adults. As this surge continues, the future of Medicare Advantage looks bright, offering hope and health to millions of seniors nationwide.

Astiva Health is committed to reshaping the landscape of personalized and comprehensive healthcare. The company offers full medical, drugs and supplemental benefits for Medicare enrollees, currently serving counties in California, including Orange, San Diego, Los Angeles, Riverside, and San Bernardino. This broad coverage reflects Astiva Health’s dedication to reaching a diverse demographic and addressing the healthcare needs of individuals across Southern California. Astiva Health is also eyeing expansion into Northern California and beyond.

For more information, visit the company’s website at www.AstivaHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to Astiva are available in the company’s newsroom at https://ibn.fm/Astiva